MA50030A - Traitement du cancer par stimulation de la production d'il-12 - Google Patents

Traitement du cancer par stimulation de la production d'il-12

Info

Publication number
MA50030A
MA50030A MA050030A MA50030A MA50030A MA 50030 A MA50030 A MA 50030A MA 050030 A MA050030 A MA 050030A MA 50030 A MA50030 A MA 50030A MA 50030 A MA50030 A MA 50030A
Authority
MA
Morocco
Prior art keywords
stimulating
production
cancer treatment
cancer
treatment
Prior art date
Application number
MA050030A
Other languages
English (en)
Inventor
Stephen Mark Anderton
Clare Louise Doris
David Festus Charles Moffat
Martin John Perry
Original Assignee
Macrophage Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrophage Pharma Ltd filed Critical Macrophage Pharma Ltd
Publication of MA50030A publication Critical patent/MA50030A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
MA050030A 2017-08-31 2018-08-30 Traitement du cancer par stimulation de la production d'il-12 MA50030A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1713975.9A GB201713975D0 (en) 2017-08-31 2017-08-31 Medical use

Publications (1)

Publication Number Publication Date
MA50030A true MA50030A (fr) 2020-07-08

Family

ID=60050569

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050030A MA50030A (fr) 2017-08-31 2018-08-30 Traitement du cancer par stimulation de la production d'il-12

Country Status (15)

Country Link
US (1) US11382902B2 (fr)
EP (1) EP3675851A1 (fr)
JP (1) JP2020536848A (fr)
KR (1) KR20200129086A (fr)
CN (1) CN111356457A (fr)
AU (1) AU2018326668A1 (fr)
BR (1) BR112020003033A2 (fr)
CA (1) CA3071550A1 (fr)
GB (1) GB201713975D0 (fr)
IL (1) IL272769A (fr)
MA (1) MA50030A (fr)
MX (1) MX2020001197A (fr)
RU (1) RU2020111355A (fr)
SG (1) SG11202000565VA (fr)
WO (1) WO2019043389A1 (fr)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
FR2790960B1 (fr) * 1999-03-15 2002-10-31 Pf Medicament Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
JP4472349B2 (ja) 2002-02-12 2010-06-02 スミスクライン ビーチャム コーポレーション ｐ３８阻害薬として有用なニコチンアミド誘導体
US20060046999A1 (en) 2002-03-14 2006-03-02 Cristina Alonso-Alija Monocyclic aroylpyridinones as antiinflammatory agents
US20060079461A1 (en) * 2003-12-24 2006-04-13 Scios, Inc. Treatment of multiple myeloma by inhibition of p38 MAP kinase
CA2607020C (fr) 2005-05-05 2015-01-13 Chroma Therapeutics Ltd. Conjugues d'ester amine alpha hydrolysables par des coarboxylesterases
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
NZ573348A (en) 2006-05-04 2012-01-12 Chroma Therapeutics Ltd p38 MAP KINASE INHIBITORS
GB0608823D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
GB0608837D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase
GB0608821D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd DHFR enzyme inhibitors
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
NZ577153A (en) 2006-10-25 2012-02-24 Chroma Therapeutics Ltd Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
GB0621203D0 (en) 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
BRPI0622100A2 (pt) 2006-10-30 2011-12-27 Chroma Therapeutics Ltd hidroxamatos como inibidores de desacetilase de histona
KR20090077975A (ko) 2006-11-01 2009-07-16 크로마 데러퓨릭스 리미티드 Ｉｋｋ-베타 세린-트레오닌 단백질 키나아제 억제제
US8106091B2 (en) 2006-11-01 2012-01-31 Chroma Therapeutics Ltd. Inhibitors of IKK-beta serine-threonine protein kinase
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
JP2011503042A (ja) 2007-11-07 2011-01-27 クロマ セラピューティクス リミテッド ｐ３８ＭＡＰキナーゼ阻害剤
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
JP5555186B2 (ja) 2008-02-29 2014-07-23 クロマ セラピューティクス リミテッド ｐ３８ＭＡＰキナーゼ阻害剤
BRPI0822522A2 (pt) 2008-04-23 2018-06-05 Chroma Therapeutics Ltd Inibidores da proteína quinase ikk-beta serina- treonina
GB0807451D0 (en) 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
US20110046210A1 (en) 2008-04-26 2011-02-24 Chroma Therapeutics Ltd. Substituted thiopenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB0907120D0 (en) 2009-04-24 2009-06-03 Chroma Therapeutics Ltd Inhibitors of IKK-ß serine-threonine protein kinase
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
GB201021467D0 (en) 2010-12-17 2011-02-02 Chroma Therapeutics Ltd Imaging agents
HK1200032A1 (en) * 2011-10-21 2015-07-31 Transgene Sa Modulation of macrophage activation
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
PT3222616T (pt) * 2012-10-17 2019-09-26 Macrophage Pharma Ltd N-[2-{4-[6-amino-5-(2,4-difluorobenzoíl)-2-oxopiridin-l(2h)-il]-3,5-difluorofenil}etil)-l-alaninato e o éster de terc-butilo do mesmo
GB201306901D0 (en) * 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination

Also Published As

Publication number Publication date
MX2020001197A (es) 2020-08-13
IL272769A (en) 2020-04-30
BR112020003033A2 (pt) 2020-08-04
US11382902B2 (en) 2022-07-12
AU2018326668A1 (en) 2020-02-20
WO2019043389A1 (fr) 2019-03-07
KR20200129086A (ko) 2020-11-17
RU2020111355A (ru) 2021-09-30
RU2020111355A3 (fr) 2021-12-16
CA3071550A1 (fr) 2019-03-07
EP3675851A1 (fr) 2020-07-08
SG11202000565VA (en) 2020-03-30
US20200360359A1 (en) 2020-11-19
JP2020536848A (ja) 2020-12-17
CN111356457A (zh) 2020-06-30
GB201713975D0 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
EP3813647A4 (fr) Stimulation multimodale de traitement des tremblements
IL283838A (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
IL269026A (en) Methods of treating tumor
EP3618829A4 (fr) Dérivés de quinazoline-pyridine pour le traitement de troubles associés à un cancer
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
PL3455258T3 (pl) Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1
EP3448263A4 (fr) Traitement électrothérapeutique
SMT202200199T1 (it) Metodi di trattamento del cancro del seno ar+.
IL275543A (en) Intratubular methods for the treatment of breast disorders
MA47408A (fr) Traitement du cancer
IL265938A (en) Lasofoxifene treatment of er+ breast cancer
MA53553A (fr) Traitement post-chirurgical de la douleur
EP3606531A4 (fr) Méthodes de traitement du cancer
EP3610026A4 (fr) Méthodes de traitement du cancer de la vessie
MA44612A (fr) Méthodes de traitement de cancers pédiatriques
WO2015197193A3 (fr) Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies
MA52627A (fr) Traitement du cancer
EP3470111C0 (fr) Stimulation du nerf vague pour traiter des troubles neurodégénératifs
LT3463351T (lt) Parkinsono ligos gydymas
LT3576740T (lt) Vėžio gydymas
IL254173B (en) Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy
EP3733175A4 (fr) Traitement du cancer
IL281600A (en) Methods of treating cancer
IL270900A (en) Treatment of cutaneous disorders
EP3862000A4 (fr) Médicament de traitement de la toux chronique